Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
ZA-300 is meant to determine the safety profile of Androxal (enclomiphene citrate) in men with secondary hypogonadism.
Secondary Hypogonadism
DRUG: Androxal
Change From Baseline in Total Morning Testosterone at 26 Weeks, Changes in values from baseline of total morning testosterone levels at Week 26, 6 months|Change From Baseline in LH, Mean change from baseline in LH at end of treatment (26 weeks), 6 months|Absolute Values of Morning Testosterone, Absolute values of morning testosterone at end of treatment (26 weeks), 6 months|Mean Change From Baseline FPG, Mean changes in Fasting Plasma Glucose from baseline to end of treatment (26 weeks), 6 months|Change From Baseline in BMI, Mean change from baseline in BMI at end of treatment (26 weeks), 6 months|Change From Baseline in FSH, Change from baseline in FSH at end of treatment (26 weeks), 6 months
This study is a phase III, open label safety study with a six month active dosing period. All subjects will be started at 12.5 mg Androxal and titrated to 25 mg if needed. Safety will be assessed by physical and visual acuity exams, slit lamp eye exams, clinical laboratory tests and adverse event reporting.